Evidence map›Paper›PMID 38193126›Full record

ArticleBioengineering & translational medicine2024

Primary T-cell-based delivery platform for in vivo synthesis of engineered proteins.

Harikrishnan Radhakrishnan, Sherri L Newmyer, Marvin A Ssemadaali, Harold S Javitz, Parijat Bhatnagar

Erratum issuedAbstract read
In one paragraph

Article in Bioengineering & translational medicine, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Syngeneic CAR T cells engineered for persistent delivery of desired proteins.Journal of controlled release : official journal of the Controlled Release Society · 2025
    Article
  3. Engineered CD4 T cells for in vivo delivery of therapeutic proteins.Proceedings of the National Academy of Sciences of the United States of America · 2024
    Article
  4. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

5 authors.

Harikrishnan RadhakrishnanBiosciences Division SRI International Menlo Park California USA.ORCID https://orcid.org/0000-0002-5435-4520
Sherri L NewmyerBiosciences Division SRI International Menlo Park California USA.ORCID https://orcid.org/0000-0003-1039-5416
Marvin A SsemadaaliBiosciences Division SRI International Menlo Park California USA.ORCID https://orcid.org/0000-0002-6869-8025
Harold S JavitzEducation Division SRI International Menlo Park California USA.ORCID https://orcid.org/0000-0002-6370-174X
Parijat BhatnagarBiosciences Division SRI International Menlo Park California USA.ORCID https://orcid.org/0000-0001-9783-3364

Funding

Self-assembled therapeutics with spatiotemporal resolutionDP2EB024245 · NIBIB · SRI INTERNATIONAL · PI BHATNAGAR, PARIJAT · 2016 to 2016
$3.0M
T-cell Biofactories for targeting extracellular matrixR33CA247739 · NCI · SRI INTERNATIONAL · PI BHATNAGAR, PARIJAT · 2020 to 2020
$1.6M
T-cell Biofactories for targeting interstitial fluid pressureR21CA236640 · NCI · SRI INTERNATIONAL · PI BHATNAGAR, PARIJAT · 2019 to 2022
$818k
NCI NIH HHS R21 CA236640NCI NIH HHS R33 CA247739NIBIB NIH HHS DP2 EB024245
6 · The paper itself

Abstract

Primary T cell has been transformed into a

Indexed as

CAR T cellscell‐based drug deliverycell engineeringcell manufacturingsynthetic biology

Identifiers

PMID38193126
PMCPMC10771566

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.